缺血性心肌病并发心力衰竭的药物联合治疗的临床分析与机制探讨

Clinical analysis and mechanism investigation of drug treatment for ischemic cardiomyopathy combined with heart failure

目的:对缺血性心肌病并发心力衰竭的药物联合治疗的临床分析与机制探讨。方法:选取某院2010年4月-2013年4月就诊的120例缺血性心肌病并发心力衰竭的患者作为研究对象,将患者随机分为2组:对照组与药物联合治疗组(n=60)。对照组给予常规治疗,药物联合治疗组在常规治疗的基础上增加阿托伐他汀和曲美他嗪联合治疗。结果:对照组治疗之后的总有效病例为48例(80%),而药物联合治疗组的总有效病例数目为57例(95%),但是2组患者均无死亡病例。药物联合治疗组患者的射血分数和左心室舒张末期内径较对照组改善明显(P<0.05),且对照组和药物联合治疗组较未治疗时均有改善(P<0.05)。药物联合治疗组血管性假性血友病因子和血浆纤维蛋白原含量明显降低(P<0.05),但是对照组无明显变化(P>0.05)。结论:药物联合应用主要通过改善心脏学指标与血液状态达到对缺血性心肌病合并心力衰竭的治疗效果。

OBJECTIVE To investigate the clinical effects and the mechanism of actions of drug treatment for ischemic car- diomyopathy combined with heart failure. METHODS 120 Patients in our hospital from Apr 2010 to Apt 2013 with ischemie cardiomyopathy and heart failure were collected and analyzed. All the patients were divided into 2 groups： control group and treatment group. The patients of treatment group were treated with atorvastatin and trimetazidine. RESULTS The effective rate was 81% in control group, and 95 % in treatment group. The ejection fraction improved in treatment group as compared with control group. It was also found that the two biotic factors were decreased in treatment group, while in the control group there was no obvious change. CONCLUSION The drug joint application improved the isehemic cardiomyopathy and heart fail- ure mainly by improving the cardiac function and the state of the blood.